|
|
|
 |
|
Metabolon Announces Founding Scientific Advisory Board |
 |
|
A Nobel Laureate and Team of Scientific Pioneers
Including J. Craig Venter Join the Metabolon Scientific Advisory Board
PRINCETON , NJ, and RESEARCH TRIANGLE PARK, NC -- (December 8, 2003)Metabolon, Inc. today announced the founding members of its Scientific Advisory Board. The Board consists of global thought leaders and pioneers in the field of metabolomics.
"Every member of our founding Scientific Advisory Board provides specific expertise and knowledge of a discipline that is critical to establishing Metabolon as a world-class leader in the field of metabolomics," said Metabolon CEO, John Ryals. "The members of our Board also share our vision of developing drugs to halt or delay the onset of neurodegenerative and other diseases."
Members of the Metabolon Scientific Advisory Board include:
Hamilton O. Smith, M.D ., Chairman of the Scientific Advisory Board, is the Scientific Director of the Institute of Biological Energy Alternatives. In 1978, Dr. Smith was a co-recipient of the Nobel Prize in Medicine for the discovery of Type II restriction enzymes, which led to the development of recombinant DNA technology. He has collaborated with The Institute for Genome Research (TIGR) to sequence the genome of H. influenza, archaea bacteria and other bacteria. He joined Celera in 1998 as Director of DNA Resources and participated in the sequencing of the genomes of the fruit fly, mosquito, mouse and human. Dr. Smith has received numerous awards and is a member of the National Academy of Sciences.
J. Craig Venter, Ph.D ., is presently the Founder and President of The J. Craig Venter Science Foundation, The Center for the Advancement of Genomics and the Institute for Biological Energy Alternatives. Dr. Venter is well known for leading Celera to the successful sequencing of the human genome. Dr. Venter held numerous research positions at the National Institutes of Health, including Chief of the Receptor Biochemistry and Molecular Biology Section. He served as President and Chairman of the Board for The Institute for Genome Research. Dr. Venter is the recipient of numerous awards and honorary degrees, including the 2001 Paul Ehrlich and Ludwig Darmstaedter Prize, the 2001 Takeda Award, the 2000 King Faisal Award and the 2002 Gairdner Foundation International Award. Dr. Venter is a member of the National Academy of Sciences.
Paul Schimmel, Ph.D. , Scientific Advisory Board member and Co-Founder, is a professor at The Scripps Research Institute. He formerly was a professor of biochemistry and biophysics in the Department of Biology at MIT. Professor Schimmel co-founded Alkermes, Cubist, Repligen and Alnylan. He was elected to membership in the National Academy of Sciences, the American Academy of Arts and Sciences and the American Philosophical Society. Professor Schimmel was a recipient of the American Chemical Society's Pfizer Award in Enzyme Chemistry and was a co-recipient of the Biophysical Society's Emily M. Gray Award for significant contributions to education in biophysics.
Oliver Smithies, D. Phil. , is a professor of pathology and laboratory medicine at the University of North Carolina at Chapel Hill. Dr. Smithies was a professor at the University of Wisconsin for 28 years prior to UNC. Dr. Smithies is well known for his pioneering work in targeted homologous recombination in transgenic mice. Among his many career honors are the Gairdner Award, the Alfred P. Sloan Award, the Ciba Award, the Bristol-Meyers-Squibb Award and the Albert Lasker Award.
M. Flint Beal, M.D. , is the Chairman of the Department of Neurology and Neuroscience at the Weill Medical College of Cornell University and Director of the Neurology Service at the New York Presbyterian Cornell Campus. Dr. Beal was professor of neurology at the Harvard Medical School and Chief of the Neurochemistry Laboratory at Massachusetts General Hospital before moving to Cornell. Dr. Beal is an internationally recognized authority on neurodegenerative disorders and is the author or co-author of more than 300 scientific articles and more than 100 books, book chapters and reviews.
Donald W. Kufe, M.D ., is Chief of Cancer Pharmacology in the Department of Adult Oncology at the Dana-Farber Cancer Institute, Director of the Harvard Phase I Oncology Program and a professor of medicine at Harvard Medical School. His work on the MUC1 antigen has provided the foundation for clinical trials of vaccines in the treatment of breast cancer. Dr. Kufe has received the American Cancer Society Faculty Award and the Burroughs-Wellcome Scholar Award. He is co-editor of the widely recognized textbook, Cancer Medicine.
About Metabolon:
Metabolon is a leader in the application of metabolomics, a powerful and new scientific approach for the discovery and development of drugs and the early diagnosis of disease states. Seasoned and successful entrepreneurs, as well as scientific pioneers, make up Metabolon's executive management team and boards.
Metabolon's patent-pending technology is poised to dramatically impact drug discovery and development processes by accurately measuring the spectrum of biochemical changes and mapping these changes to metabolic pathways. Metabolon's technology can identify safer compounds for development, shorten the time for drugs to get to market and identify diagnostic markers for earlier disease detection.
Back to Portfolio News
|
|
